Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Cytokines, a broad category of small proteins involved in cell signaling, are increasingly being studied and used in the management of autoimmune disorders. The rationale for their use is rooted in scientific understanding of immune system dysregulation that underlies most autoimmune diseases. Certain cytokines—such as interferons (IFNs) and interleukins (ILs)—have been developed as biologic therapies to modulate immune responses. For example, interferon-beta (a cytokine) is approved and widely used for relapsing forms of multiple sclerosis, where it reduces the frequency and severity of relapses by modulating inflammatory processes. Similarly, monoclonal antibodies targeting pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) or interleukin-6 (IL-6) have dramatically improved outcomes in diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis. However, these therapies are not simply administration of "cytokines" in a general sense, but rather targeted use of specific cytokines or cytokine inhibitors. While substantial scientific evidence supports the therapeutic targeting of cytokine pathways in autoimmune diseases, the direct use of unspecified cytokines is not a standard approach outside of controlled clinical settings. Clinical use is thus highly specific, and the overall evidence rating is moderate because efficacy and safety vary depending on the cytokine, disease, and individual patient factors. Ongoing research continues to refine and expand cytokine-based therapies.

More about Cytokines
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by Cytokines

Products containing Cytokines